Achieve Life Sciences, Inc. announced its financial results for Q4 and the year-end 2024, while reaffirming plans to submit a new drug application (NDA) for cytisinicline, a treatment for nicotine ...
More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results